EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults

Emma Boström, Sagar S Bachhav, Hao Xiong, Cindy Zadikoff, Qingbo Li, Eric Cohen, Ingeborg Dreher, Anna Torrång, Gunilla Osswald, Mikael Moge, Paulina Appelkvist, Johanna Fälting und 1 weitere

The Journal of Clinical Pharmacology · 2024-11 · 64 (11) · 1432-1442

DOI: 10.1002/jcph.6103 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 06.08.2024. Verfasst von Emma Boström und 12 weiteren Autor:innen. Beteiligte Einrichtung: BioArctic AB, Stockholm, Sweden. Hauptthemen laut MEDLINE: alpha-Synuclein, East Asian People, White People. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exidavnemab is a monoclonal antibody (mAb) with a high affinity and selectivity for pathological aggregated forms of α‐synuclein and a low affinity for physiological monomers, which is in clinical development as a disease‐modifying treatment for patients with synucleinopathies such as Parkinson's disease. Safety, tolerability, pharmacokinetics, immunogenicity, and exploratory biomarkers were assessed in two separate Phase 1 single ascending dose studies, including single intravenous (IV) (100 to 6000 mg) or subcutaneous (SC) (300 mg) administration of exidavnemab in healthy volunteers (HVs). Across the two studies, a total of 98 Western, Caucasian, Japanese, and Han Chinese HVs were enrolled, of which 95 completed the study. Exidavnemab was generally well tolerated. There were no serious adverse events or safety issues identified in laboratory analyses. Headache, asymptomatic COVID‐19, back pain, and post lumbar puncture syndrome were the most frequently reported treatment‐emergent adverse events. Following IV infusion, the pharmacokinetics of exidavnemab was approximately dose linear in the range 100‐6000 mg. The terminal half‐life was approximately 30 days, and the exposure was comparable across Western, Caucasian, Japanese, and Han Chinese volunteers. The absolute SC bioavailability was ∼71%. Cerebrospinal fluid exposure relative to serum after single dose was within the range expected for mAbs (approximately 0.2%). The anti‐drug antibody rates were low and there was no effect of immunogenicity on the pharmacokinetics or safety. Dose‐dependent reduction of free α‐synuclein in plasma was observed. In summary, exidavnemab was found to have an excellent pharmacokinetic profile and was well tolerated in HVs, supporting the continued clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinEast Asian PeopleWhite PeopleAdultFemaleHumansMaleMiddle AgedYoung AdultAntibodies, Monoclonal, HumanizedDose-Response Relationship, DrugHalf-LifeHealthy VolunteersInfusions, IntravenousInjections, Subcutaneous

Stichwörter der Autor:innen

AsianParkinson's diseasemonoclonal antibodyneuronal synuclein diseasepharmacokineticsα‐synuclein

Substanzen

alpha-SynucleinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • BioArctic AB, Stockholm, Sweden.
  • AbbVie Inc., North Chicago, IL, USA.
  • SDS Life Science AB, Stockholm, Sweden.

Zitieren

APA

Boström, E., Bachhav, S. S., Xiong, H., Zadikoff, C., Li, Q., Cohen, E., Dreher, I., Torrång, A., Osswald, G., Moge, M., Appelkvist, P., Fälting, J., & Odergren, T. (2024). Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults. The Journal of Clinical Pharmacology, 64(11), 1432-1442. https://doi.org/10.1002/jcph.6103

Vancouver

Boström E, Bachhav SS, Xiong H, Zadikoff C, Li Q, Cohen E, et al. Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults. The Journal of Clinical Pharmacology. 2024;64(11):1432-1442. doi:10.1002/jcph.6103

BibTeX
@article{Bostrm2024,
  author = {Boström, Emma and Bachhav, Sagar S and Xiong, Hao and Zadikoff, Cindy and Li, Qingbo and Cohen, Eric and Dreher, Ingeborg and Torrång, Anna and Osswald, Gunilla and Moge, Mikael and Appelkvist, Paulina and Fälting, Johanna and Odergren, Tomas},
  title = {Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  volume = {64},
  number = {11},
  pages = {1432--1442},
  doi = {10.1002/jcph.6103}
}
Kostenlos starten →